2026-04-10 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement of our selection as one of the "Digital Transformation Stocks (DX Stocks) 2026".”
2026-04-10 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement of our selection as one of the "Digital Tra … 続きを読む
JP3519400000
2026-04-09 CHUGAI PHARMACEUTICAL CO.,LTD. “Notice of discontinuation of co-marketing of the anti-CD20 monoclonal antibody "Rituxan®".”
2026-04-09 CHUGAI PHARMACEUTICAL CO.,LTD. “Notice of discontinuation of co-marketing of the anti-CD20 mo … 続きを読む
2026-04-06 CHUGAI PHARMACEUTICAL CO.,LTD. “Research findings on immune thrombocytopenia, conducted in collaboration with the Immunology Frontier Research Center at Osaka University, have been published in the journal Blood.”
2026-04-06 CHUGAI PHARMACEUTICAL CO.,LTD. “Research findings on immune thrombocytopenia, conducted in co … 続きを読む
2026-04-02 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding Eli Lilly's announcement about the oral GLP-1 receptor agonist Foundayo™ (olformlipron).”
2026-04-02 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding Eli Lilly's announcement about the oral GLP-1 r … 続きを読む
2026-03-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding our thinking and policies on reducing the investment unit.”
2026-03-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding our thinking and policies on reducing the investmen … 続きを読む
2026-03-23 CHUGAI PHARMACEUTICAL CO.,LTD. “Notice Regarding the Discontinuation of Development of GYM329 (emugrobart) for Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy.”
2026-03-23 CHUGAI PHARMACEUTICAL CO.,LTD. “Notice Regarding the Discontinuation of Development of GYM329 … 続きを読む
2026-03-23 CHUGAI PHARMACEUTICAL CO.,LTD. “The combination therapy of Lunsumio and Polaiby has received approval for an additional indication: relapsed or refractory large B-cell lymphoma.”
2026-03-23 CHUGAI PHARMACEUTICAL CO.,LTD. “The combination therapy of Lunsumio and Polaiby has received … 続きを読む
None None “。”
None None “。”